Literature DB >> 9402018

The role of ribosomal RNAs in macrolide resistance.

P Sander1, T Prammananan, A Meier, K Frischkorn, E C Böttger.   

Abstract

Macrolides are bacteriostatic antibiotics which interfere with the peptidyltransfer function of the ribosome. We have investigated the molecular mechanisms underlying macrolide resistance in Mycobacterium smegmatis, an eubacterium carrying two rRNA operons. Surprisingly, drug resistance was associated not with alterations in ribosomal proteins, but with a single point mutation in the peptidyltransferase region of one of the two 23S RNA genes, i.e. A2058-->G or A2059-->G. This mutation resulted in a heterozygous organism with a mutated and a wild-type rRNA operon respectively. Reverse transcriptase sequencing indicated the expression of both wild-type and mutated rRNAs. The mutated operon was introduced into genetically engineered rrn- strains of M. smegmatis carrying a single functional rRNA operon and into parental M. smegmatis with two chromosomal rRNA operons, using gene transfer as well as gene replacement techniques. The results obtained demonstrate the dominant nature of resistance. As exemplified in our results on macrolide resistance, a complete set of genetic tools is now available, which allows questions of dominance vs. recessivity and gene dosage effects in eubacterial ribosomal nucleic acids to be addressed experimentally in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9402018     DOI: 10.1046/j.1365-2958.1997.5811946.x

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  32 in total

Review 1.  Macrolide resistance conferred by base substitutions in 23S rRNA.

Authors:  B Vester; S Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  Structural basis for selectivity and toxicity of ribosomal antibiotics.

Authors:  E C Böttger; B Springer; T Prammananan; Y Kidan; P Sander
Journal:  EMBO Rep       Date:  2001-04       Impact factor: 8.807

3.  A point mutation associated with bacterial macrolide resistance is present in both 23S rRNA genes of an erythromycin-resistant Treponema pallidum clinical isolate.

Authors:  L V Stamm; H L Bergen
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 4.  Mutation frequencies and antibiotic resistance.

Authors:  J L Martinez; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

5.  Fitness cost of chromosomal drug resistance-conferring mutations.

Authors:  Peter Sander; Burkhard Springer; Therdsak Prammananan; Antje Sturmfels; Martin Kappler; Michel Pletschette; Erik C Böttger
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium.

Authors:  K A Nash
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

7.  Molecular mechanisms by which rRNA mutations confer resistance to clindamycin.

Authors:  Jacob Poehlsgaard; Peter Pfister; Erik C Böttger; Stephen Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

8.  Phylogenetic sequence variations in bacterial rRNA affect species-specific susceptibility to drugs targeting protein synthesis.

Authors:  Subramanian Akshay; Mihai Bertea; Sven N Hobbie; Björn Oettinghaus; Dimitri Shcherbakov; Erik C Böttger; Rashid Akbergenov
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

9.  Mitochondrial ribosome as the target for the macrolide antibiotic clarithromycin in the helminth Echinococcus multilocularis.

Authors:  Alexander Mathis; Peter Wild; Erik C Boettger; Christian M O Kapel; Peter Deplazes
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 10.  Resistance to Macrolide Antibiotics in Public Health Pathogens.

Authors:  Corey Fyfe; Trudy H Grossman; Kathy Kerstein; Joyce Sutcliffe
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.